isavuconazonium (cresemba) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cytoplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$88.8393 - $411.6350
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

bal8557 | bal 8557 | bal-8557 | bal8557-000 | bal8557-002 | cresemba | isavuconazole | isavuconazonium | isavuconazonium chloride | isavuconazonium sulfate | ro0098557

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue